リセプターチロシンキナーゼエフB3のための特定の,不可逆的な阻害剤の開発
Alvin Kung, Ying-Chu Chen, Marianne Schimpl1
1Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Building 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, United Kingdom.
Journal of the American Chemical Society
|August 2, 2016
まとめ
研究者は,EphB3受容体チロシンキナーゼ (RTK) に対する最初の特定の小分子阻害剤を開発した. これらの標的型阻害剤は,構造的な洞察を用いて設計され,細胞生物学と疾患におけるEphB3の役割の詳細な研究を可能にします.
科学分野:
- 生物化学
- 分子生物学
- 薬理学について
背景:
- エリトポエチン産生ヒト肝細胞がん (Eph) 受容体チロシンキナーゼ (RTK) は,移動や増殖などの細胞過程の重要な調節因子です.
- イソフォーム特異の小分子阻害剤の開発は,家族内の高い同質性のために困難です.
研究 の 目的:
- 単一のエフ isoform,エフB3をターゲットとする最初の強力で特定の小分子阻害剤を開発する.
- これらの阻害剤を使用して,EphB3の生物学的機能と疾患への貢献を調べる.
主な方法:
- EphB3のユニークな特徴を特定するための構造バイオインフォマティック分析.
- 電子性キナゾリン阻害剤の合成と特徴付け
- 阻害剤の効能と選択性を評価するためのインビトロおよび細胞測定法.
- コクリスタログラフィーは,阻害剤の結合とメカニズムを確認する.
- プロテオーム全体のターゲットエンゲージメント研究のための"クリック可能な"阻害剤の開発.
主要な成果:
- エフB3キナーゼのヒンドル領域のユニークなシステインの識別.
- エフB3をインビトロおよび細胞内で強力に阻害する選択性キナゾリン阻害剤の開発.
- コクリスタル構造は,EphB3の共性阻害を確認しています.
- 特定の阻害剤を用いたEphB3のトランス自己リン酸化の実証.
結論:
- 開発された阻害剤は,EphB3を標的とする最初の強力で特定のツールです.
- これらの阻害剤は,生物学的プロセスと疾患におけるEphB3の特定の役割の解剖に非常に役立ちます.
- この研究は,アイソフォーム選択性キナーゼ阻害剤の開発のための新しい戦略を提供します.
関連する概念動画
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Transducer Mechanism: Enzyme-Linked Receptors
4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.7K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Receptor Tyrosine Kinases
20.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K
Receptor Downregulation in MVBs
2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.9K


